Human Antibody Core

人类抗体核心设备是基于俄克拉荷马州大学开发的一项技术 医学研究基金会。这项技术有助于生产全人类、全长、抗原特异性的 单克隆抗体。这一过程可在感染后短短28天内完成或 免疫，并创建全长，正确配对的抗体任何所需的免疫球蛋白亚类。 作为一个核心设施，我们已经为包括小说在内的各种目的生产了人类单克隆体 诊断学，被动免疫疗法，最重要的是，了解人类对 接种疫苗。我们目前有一个超过900个单抗的资料库。已知的细节 包括季节性和大流行性H1N1、H3N2和B型流感病毒株、肺炎链球菌囊状 多糖、狂犬病和牛痘病毒以及炭疽保护性抗原(PA)。特别是，我们的抗体 对来自接种了被吸收的炭疽疫苗的个体的炭疽保护性抗原(PA) (AVA)，以及与复杂构象表位结合的两种抗体 无论是在体外还是在体内，PA都被证明对致死毒素攻击具有保护作用。我们的核心设施 用以前作为合作中心成员的资金制作了这些抗PA单克隆 在过去的六年里，人类免疫学。

The Human Antibody Core Facility is based on a technology that was developed at the Oklahoma Medical Research Foundation. The technology facilitates the production of fully human, full-length, antigen-specific monoclonal antibodies. The process can be completed in as little as 28 days post infection or immunization and creates full-length, properly paired antibodies of any desired IgG subclass. As a core facility, we have produced human monoclonals for a variety of purposes including novel diagnostics, passive immunotherapeutics and most importantly, understanding human immune responses to vaccination. We currently have a library of over nine hundred monoclonal antibodies. Known specificities include seasonal and pandemic H1N1, H3N2 and B influenza strains, S. pneumoniae capsular polysaccharide, rabies and vaccinia virus, and anthrax protective antigen (PA). In particular, our antibodies to anthrax protective antigen (PA), derived from an individual vaccinated with Anthrax Vaccine Absorbed (AVA), were carefully characterized, and two antibodies which bound to complex conformational epitopes of PA were shown to be protective against lethal toxin challenge both in vitro and in vivo. Our core facility produced these anti-PA monoclonals with previous funding as a member of the Cooperative Centers for Human Immunology during the last six years.